Core Insights - Sensei Biotherapeutics reported promising preliminary efficacy data for solnerstotug in patients resistant to PD-(L)1 therapy, showing durable responses and tumor shrinkage [1][2] - The company achieved target enrollment in the dose expansion cohort and expects full data by the end of 2025 [1][9] - Sensei's cash position is projected to fund operations into the second quarter of 2026 [11] Clinical Development - Solnerstotug is designed to target the immune checkpoint VISTA, which is associated with poor survival rates in various cancers [3] - The ongoing Phase 1/2 clinical trial is evaluating solnerstotug as a monotherapy and in combination with Regeneron's PD-1 inhibitor Libtayo® [4] - Preliminary data indicated a 14% overall response rate (ORR) and a 62% disease control rate (DCR) in evaluable PD-(L)1 resistant "hot" tumor patients [8] Safety Profile - Solnerstotug has shown a favorable safety profile, with no dose-limiting toxicities reported and most adverse events being Grade 1 or 2 [6] - Among 60 patients, only four (7%) experienced mild Grade 1 cytokine release syndrome [6] Financial Performance - As of December 31, 2024, the company reported cash, cash equivalents, and marketable securities totaling $41.3 million, down from $65.8 million in 2023 [11] - Research and development expenses increased slightly to $18.6 million in 2024 from $18.3 million in 2023, primarily due to clinical trial costs [12] - General and administrative expenses decreased to $13.0 million in 2024 from $18.8 million in 2023, attributed to lower external service costs [13] Corporate Updates - The company has made organizational changes to streamline operations and focus on advancing solnerstotug [16] - Key appointments include Josiah Craver as Senior Vice President of Finance and Ron Weitzman, M.D., as part-time Chief Medical Officer [16]
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress